Congenital Adrenal Hyperplasia (CAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Congenital Adrenal Hyperplasia (CAH) Market Outlook

Thelansis’s “Congenital Adrenal Hyperplasia (CAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Adrenal Hyperplasia (CAH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Congenital Adrenal Hyperplasia (CAH) Overview

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive adrenal steroidogenesis disorders, with 21-hydroxylase deficiency caused by CYP21A2 mutations accounting for over 90% of cases, disrupting cortisol and aldosterone biosynthesis while redirecting steroid precursors toward androgen excess. Disease severity spans classic salt-wasting CAH presenting neonatally with adrenal crisis, hyponatraemia, hyperkalaemia, and virilisation, through simple virilising and non-classic forms manifesting with premature adrenarche, hirsutism, menstrual irregularity, and subfertility. Newborn screening via 17-hydroxyprogesterone measurement enables early diagnosis, confirmed by CYP21A2 genotyping and adrenal steroid profiling. Glucocorticoid replacement suppresses ACTH-driven androgen excess while restoring deficient cortisol; mineralocorticoid replacement with fludrocortisone addresses salt-wasting. Balancing glucocorticoid dosing remains clinically challenging, as under-replacement perpetuates androgen excess while over-replacement risks iatrogenic Cushing syndrome and growth suppression. Crinecerfont, an approved CRF1 receptor antagonist, represents a paradigm-shifting adjunctive therapy reducing androgen excess and enabling glucocorticoid dose reduction in eligible patients, while tildacerfont and other agents remain in active development. Adrenal crisis prevention through sick-day rules and emergency hydrocortisone is critical. Prognosis is favourable with adherence; endocrinological surveillance, psychological support, and multidisciplinary patient-centred care are integral to optimising lifelong outcomes.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025–2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Congenital Adrenal Hyperplasia (CAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035


Comments

Post a Comment